MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Holdings in Kymera Therapeutics, Inc. (NASDAQ: KYMR)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. expanded its holdings in Kymera Therapeutics, Inc. (NASDAQ: KYMR– Free Report) by 7.5% in the 4th quarter, according to its most recent 13F declaring with the Securities and Exchange Compensation (SEC). The firm owned 28,960 shares of the business’s supply after getting an added 2,011 shares during the quarter.
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Kymera Therapeutics, Inc. (NASDAQ: KYMR– Free Report) by 7.5% in the 4th quarter, according to its latest 13F declaring with the Stocks and Exchange Commission (SEC). The firm possessed 28,960 shares of the company’s supply after buying an added 2,011 shares throughout the quarter. MIRAE PROPERTY GLOBAL ETFS HOLDINGS Ltd.’s holdings in Kymera Therapies were worth $1,163,000 at the end of one of the most current quarter.
Other Institutional Investors Modifications in Holdings:
A variety of other institutional investors have likewise just recently modified their holdings of KYMR. Blue Trust Inc. elevated its position in Kymera Therapies by 74.8% in the 4th quarter. Blue Trust Inc. now has 631 shares of the firm’s stock worth $25,000 after obtaining an added 270 shares in the last quarter. KBC Team NV enhanced its holdings in shares of Kymera Therapies by 53.8% in the 4th quarter. KBC Group NV now possesses 2,151 shares of the company’s stock valued at $87,000 after buying an extra 752 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its risk in shares of Kymera Rehabs by 10.6% in the fourth quarter. China Universal Possession Management Co. Ltd. now possesses 13,733 shares of the firm’s supply valued at $552,000 after purchasing an added 1,311 shares throughout the period. Rhumbline Advisers increased its holdings in Kymera Therapeutics by 3.0% throughout the fourth quarter. Rhumbline Advisers currently has 64,157 shares of the company’s supply worth $2,581,000 after getting an added 1,861 shares in the last quarter. Finally, Bank of New York City Mellon Corp boosted its holdings in Kymera Therapies by 4.5% throughout the fourth quarter. Bank of New York Mellon Corp currently possesses 127,093 shares of the business’s supply worth $5,113,000 after purchasing an added 5,448 shares in the last quarter.
Kymera Therapy Rate Performance:
KYMR opened up at $29.49 on Monday. Kymera Rehabs, Inc. has a one-year low of $19.45 and a 12-month high of $53.27. The business has a 50-day moving average of $28.96 and a two-hundred day relocating standard of $36.29. The supply has a market capitalization of $1.92 billion, a price-to-earnings proportion of -12.60 and a beta of 2.18. Kymera Rehabs (NASDAQ: KYMR– Break Out Report) last launched its profits outcomes on Friday, May 9th.
Wall Surface Road Expert Weigh In:
A variety of equities research study analysts have lately provided records on KYMR shares. Wall Road Zen updated shares of Kymera Therapies from a ‘sell’ rating to a ‘hold’ rating in a research study record on Thursday. HC Wainwright enhanced their target price on Kymera Therapies from $54.00 to $60.00 and provided the supply a ‘buy’ score in a research record on Friday, February 28th. Stifel Nicolaus launched insurance coverage on Kymera Therapies in a record on Tuesday, May 20th. They provided a ‘get’ score and a $55.00 target price on the stock. Financial institution of America cut their price target on Kymera Rehabs from $47.00 to $44.00 and established a ‘neutral’ ranking for the firm in a study note on Monday, May 12th. Finally, Guggenheim restated a ‘acquire’ rating and released a $52.00 price objective on shares of Kymera Therapeutics in a research study record on Monday, May 12th. Five analysts have actually rated the supply with a hold ranking, twelve have given a buy rating and one has offered a solid buy score to the company’s supply. According to MarketBeat.com, the supply currently has an average score of ‘Moderate Buy’ and a consensus cost target of $55.25.
Insider Buying and Selling at Kymera Therapeutics:
In various other Kymera Therapies news, CFO Bruce N. Jacobs offered 7,035 shares of Kymera Therapies supply in a transaction that occurred on Monday, March 3rd. The shares were sold at an ordinary cost of $30.45, for a total deal of $214,215.75. Complying with the transaction, the chief financial police officer now straight owns 201,886 shares of the firm’s stock, valued at $6,147,428.70. The profession was a 3.37% decrease in their ownership of the stock. The sale was divulged in a filing with the SEC, which is accessible via this link. Additionally, COO Jeremy G. Chadwick offered 1,383 shares of the supply in a transaction on Monday, March 3rd. The supply was cost an average cost of $30.45, for a complete purchase of $42,112.35. Adhering to the conclusion of the sale, the chief running police officer currently straight owns 67,800 shares of the firm’s stock, valued at $2,064,510. The trade was a 2.00% decline in their position. The disclosure for this sale can be found here. Experts have actually offered an overall of 10,659 shares of firm supply worth $324,567 in the last quarter. 16.01% of the stock is had by experts.
About Kymera Therapeutics (Free Report):
Kymera Therapeutics, Inc, a biopharmaceutical business, focuses on uncovering and developing novel tiny molecule therapies that selectively deteriorate disease-causing healthy proteins by using the body’s own all-natural healthy protein deterioration system. It participates in creating IRAK4 program, which remains in Phase II scientific trial for the therapy of immunology-inflammation diseases, consisting of hidradenitis suppurativa, atopic dermatitis; STAT3 program for the therapy of hematologic malignancies and strong tumors, as well as autoimmune illness and fibrosis; and MDM2 program to deal with hematological hatreds and solid tumors.
